{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:18Z","timestamp":1792190598878,"version":"4.4.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study comprehensively analyzed the global clinical trials and depicted a landscape of immune checkpoint inhibitors (ICIs) in thyroid cancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study leveraged the Trialtrove database (https:\/\/clinicalintelligence.citeline.com\/) to conduct a systematic analysis of the clinical trial landscape in thyroid cancer research. Utilizing professional medical subject headings, we performed a comprehensive search with keywords such as \u201cImmune checkpoint inhibitor\u201d and \u201cThyroid oncology,\u201d identifying a total of 113 clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our review of 113 trials revealed a peak in 2020, primarily driven by phase II and III studies. Pembrolizumab was the most frequently studied monotherapy, while combinations such as Pembrolizumab-Lenvatinib and Camrelizumab-Apatinib were also evaluated. Biomarkers like BRAF and immune checkpoint markers were prominently investigated. Although most trials achieved their primary endpoints, only five reported positive outcomes. Our analysis underscores the importance of specific thyroid cancer subtypes and novel combination therapies in advancing ICIs applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The study presents some valuable insights regarding the present state and future perspectives of clinical trials on thyroid cancer<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002830","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T11:01:52Z","timestamp":1751540512000},"page":"7346-7349","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Immune checkpoint inhibitors against thyroid cancer"],"prefix":"10.1097","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0711-7335","authenticated-orcid":false,"given":"Kun","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital South Campus, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2822-9785","authenticated-orcid":false,"given":"Libo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital South Campus, Shanghai, China"},{"name":"Department of Nuclear Medicine, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"158\u201366","DOI":"10.1089\/thy.2023.0542","article-title":"The combined effect of immune checkpoint inhibitors and tyrosine kinase inhibitors on thyroid function","volume":"34","author":"Tsai","year":"2024","journal-title":"Thyroid"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"2186\u201399","DOI":"10.1038\/s41590-024-02015-4","article-title":"Next-generation combination approaches for immune checkpoint therapy","volume":"25","author":"Goswami","year":"2024","journal-title":"Nat Immunol"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"1663\u201371","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1036\u201343","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"R5-20260109","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence-the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijsu.2017.02.064","article-title":"Genetics of medullary thyroid cancer: an overview","volume":"41","author":"Accardo","year":"2017","journal-title":"Int J Surg"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"491\u2013501","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"1615\u201322","DOI":"10.1089\/thy.2019.0086","article-title":"A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"1672\u201380","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"1753\u201368","DOI":"10.1097\/JS9.0000000000000368","article-title":"Toxicities associated with immune checkpoint inhibitors: a systematic study","volume":"109","author":"Kong","year":"2023","journal-title":"Int J Surg"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:01:40Z","timestamp":1767963700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002830","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"2025-04-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}